BioCentury | Apr 11, 2019
Finance

Syncona eyes a matching pair

...available for licensing to other gene therapy companies, as it had always been. One company, BioTime...
BioCentury | Feb 1, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

...in cell-free DNA (cfDNA) from the blood of patients with non-small cell lung cancer (NSCLC). BioTime...
BioCentury | Jan 29, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

...250 patient blood samples. The news sent the company’s shares soaring $4.09 (225%) to $5.91. BioTime...
BioCentury | Jan 25, 2019
Clinical News

Asterias' oligodendrocyte progenitor cell therapy improves motor function in SCI patients at 12 months

...will provide an update on the program this year after the company's proposed merger with BioTime...
BioCentury | Jan 18, 2019
Financial News

Juvenescence raises first tranche of $100M series B

...Medicine Inc. (Rockville, Md.), LyGenesis Inc. (Pittsburgh, Pa.) and the AgeX Therapeutics Inc. subsidiary of BioTime...
BioCentury | Jan 16, 2019
Financial News

Juvenescence raises first tranche of $100M series B

...Medicine Inc. (Rockville, Md.), LyGenesis Inc. (Pittsburgh, Pa.) and the AgeX Therapeutics Inc. subsidiary of BioTime...
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...April 30. The life science supply company is searching for a successor. Degenerative disease company BioTime...
BioCentury | Sep 18, 2018
Company News

Management tracks: BioTime, Immune-Onc

...Degenerative disease company BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX) named Brian Culley CEO, to replace co-CEOs Adi...
...SVP, general counsel and corporate secretary at Iroko Pharmaceuticals LLC (Philadelphia, Pa.). BC Staff Achaogen Inc. Artemis Therapeutics Inc. BioTime...
BioCentury | Jun 16, 2018
Finance

Rejuvenating aging

...includes three companies, Insilico Medicine Inc., LyGenesis Inc. and the AgeX Therapeutics Inc. subsidiary of BioTime...
...began our series A road show, which was very well received.” Chris Lieu, Staff Writer AgeX Therapeutics Inc. BioTime...
BioCentury | Jun 15, 2018
Financial News

Juvenescence raises $50M series A

...Medicine Inc. (Baltimore, Md.), LyGenesis Inc. (Pittsburgh, Pa.) and the AgeX Therapeutics Inc. subsidiary of BioTime...
...clinical development. Juvenescence Ltd., Douglas, Isle of Man BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX), Alameda, Calif. Chris Lieu BioTime...
Items per page:
1 - 10 of 183
BioCentury | Apr 11, 2019
Finance

Syncona eyes a matching pair

...available for licensing to other gene therapy companies, as it had always been. One company, BioTime...
BioCentury | Feb 1, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

...in cell-free DNA (cfDNA) from the blood of patients with non-small cell lung cancer (NSCLC). BioTime...
BioCentury | Jan 29, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

...250 patient blood samples. The news sent the company’s shares soaring $4.09 (225%) to $5.91. BioTime...
BioCentury | Jan 25, 2019
Clinical News

Asterias' oligodendrocyte progenitor cell therapy improves motor function in SCI patients at 12 months

...will provide an update on the program this year after the company's proposed merger with BioTime...
BioCentury | Jan 18, 2019
Financial News

Juvenescence raises first tranche of $100M series B

...Medicine Inc. (Rockville, Md.), LyGenesis Inc. (Pittsburgh, Pa.) and the AgeX Therapeutics Inc. subsidiary of BioTime...
BioCentury | Jan 16, 2019
Financial News

Juvenescence raises first tranche of $100M series B

...Medicine Inc. (Rockville, Md.), LyGenesis Inc. (Pittsburgh, Pa.) and the AgeX Therapeutics Inc. subsidiary of BioTime...
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...April 30. The life science supply company is searching for a successor. Degenerative disease company BioTime...
BioCentury | Sep 18, 2018
Company News

Management tracks: BioTime, Immune-Onc

...Degenerative disease company BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX) named Brian Culley CEO, to replace co-CEOs Adi...
...SVP, general counsel and corporate secretary at Iroko Pharmaceuticals LLC (Philadelphia, Pa.). BC Staff Achaogen Inc. Artemis Therapeutics Inc. BioTime...
BioCentury | Jun 16, 2018
Finance

Rejuvenating aging

...includes three companies, Insilico Medicine Inc., LyGenesis Inc. and the AgeX Therapeutics Inc. subsidiary of BioTime...
...began our series A road show, which was very well received.” Chris Lieu, Staff Writer AgeX Therapeutics Inc. BioTime...
BioCentury | Jun 15, 2018
Financial News

Juvenescence raises $50M series A

...Medicine Inc. (Baltimore, Md.), LyGenesis Inc. (Pittsburgh, Pa.) and the AgeX Therapeutics Inc. subsidiary of BioTime...
...clinical development. Juvenescence Ltd., Douglas, Isle of Man BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX), Alameda, Calif. Chris Lieu BioTime...
Items per page:
1 - 10 of 183